| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
* Department of Medicine and Department of Immunology, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045;
Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL 32610; and
North Florida South Georgia Veterans Health System, Gainesville, FL 32608
The Sle1c lupus susceptibility interval spans a 7-Mb region on distal murine chromosome 1. Cr2 is the strongest candidate gene for lupus susceptibility in this interval, as its protein products are structurally and functionally altered. B6.Sle1c congenic mice develop Abs to chromatin by 9 mo of age with a 30% penetrance and do not develop GN. To determine whether the New Zealand White (NZW)-derived Sle1c interval would interact with New Zealand Black (NZB) genes to result in enhanced autoimmune phenotypes, NZB mice were bred with B6 or B6.Sle1c congenic mice and 
20 female offspring were selected from each breeding for longitudinal study. These mice differ only at the Sle1c locus at which they have either a NZB/B6 or NZB/NZW genotype. NZB x B6.Sle1c mice had an accelerated onset of anti-chromatin Abs (100 vs 68% at 6 mo, p = 0.006) and anti-dsDNA Abs (45 vs 5% at 9 mo, p = 0.0048). Furthermore, median titers of anti-chromatin and anti-dsDNA Abs were significantly higher in the NZB x B6.Sle1c group compared with the NZB x B6 group. This corresponded with a higher prevalence of proliferative GN at 12 mo (55 vs 16%, p = 0.0214) as well as increased glomerular deposition of C3 (p = 0.0272) and IgG (p = 0.032), although blood urea nitrogen remained normal and significant proteinuria was not identified in either group. These data show that the Sle1c interval accelerates and augments the loss of tolerance to chromatin and dsDNA induced by NZB genes and induces significantly greater end-organ damage.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by an Arthritis Foundation Arthritis Investigator Award (to S.A.B.) and National Institutes of Health Grants R0-1 AI52441 (to S.A.B.) and RO-1 AI045050 (to L.M.). The DNA samples were sequenced by the University of Colorado Cancer Center DNA Sequencing and Analysis Core, which is supported by the National Institutes of Health/National Cancer Institute Cancer Core Support Grant (P30 CA046934).
2 Address correspondence and reprint requests to Dr. Susan A. Boackle, Division of Rheumatology, University of Colorado at Denver and Health Sciences Center, Mail Stop B115, P.O. Box 6511, Aurora, Colorado 80045. E-mail address: susan.boackle{at}uchsc.edu
3 Abbreviations used in this paper: SLE, systemic lupus erythematosus; BUN, blood urea nitrogen; CR, complement receptor; Crry, CR-related gene Y; GN, glomerulonephritis; NZB, New Zealand Black; NZW, New Zealand White; PAS, periodic acid-Schiff; sIg, surface Ig.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
